A seasoned corporate builder, William R. Timmons III has demonstrated significant expertise in enhancing business growth and operational efficiency. With an extensive background across various leadership roles, he has effectively driven strategic initiatives within dynamic environments. His tenure encompasses valuable insights gained through executive positions where innovative solutions were key to market differentiation. Timmons' impact extends into areas such as mergers and acquisitions, positioning organizations for accelerated expansion and competitive advantage in their respective sectors. He remains a prominent figure in business circles, known for his ability to forge sustainable partnerships that elevate performance.
A seasoned corporate builder, William R. Timmons III has demonstrated significant expertise in enhancing business growth and operational efficiency. With an extensive background across various leadership roles, he has effectively driven strategic initiatives within dynamic environments. His tenure encompasses valuable insights gained through executive positions where innovative solutions were key to market differentiation. Timmons' impact extends into areas such as mergers and acquisitions, positioning organizations for accelerated expansion and competitive advantage in their respective sectors. He remains a prominent figure in business circles, known for his ability to forge sustainable partnerships that elevate performance.
William R. Timmons III exemplifies a transformative leadership style, harnessing operational know-how to capitalize on strategic opportunities. His extensive experience in the corporate realm informs an investment philosophy that prioritizes innovation-driven growth and competitive differentiation. Through his focus on business model enhancement, he seeks ventures positioned for substantial market share gains. The approach is underpinned by active engagement in mergers and acquisitions, aligning with firms poised for expansion within emerging sectors. With a commitment to building sustainable relationships, he effectively nurtures synergies that promote long-term value creation.
William R. Timmons III exemplifies a transformative leadership style, harnessing operational know-how to capitalize on strategic opportunities. His extensive experience in the corporate realm informs an investment philosophy that prioritizes innovation-driven growth and competitive differentiation. Through his focus on business model enhancement, he seeks ventures positioned for substantial market share gains. The approach is underpinned by active engagement in mergers and acquisitions, aligning with firms poised for expansion within emerging sectors. With a commitment to building sustainable relationships, he effectively nurtures synergies that promote long-term value creation.
| Trades 1425 | Longs Won 879/1425 61% | Profit Factor 2.77 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $1.29M |
| Average Win $668,693.18 | Best Trade (Aug 10) $15.11M | Sharpe Ratio -24.26 |
| Average Loss -$388,659.26 | Worst Trade (Dec 30) -$10.44M | Z-Score -4.15 (100%) |
| Commissions $0 | Avg. Trade Length 4y 2m 3w 6d | Expectancy $263,560.24 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 1,203 | 1,083 | 963 | 842 | 722 | 602 | 481 | 361 | 241 | 120 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
ABBV AbbVie Inc. | 92,500 | $9.06M | $24.25M | - | $15.19M | 167.67% | -1.532% |
ABT Abbott Laboratories | 90,000 | $7.76M | $8.99M | - | $1.23M | 15.79% | -1.07% |
AIR AAR Corp. | 80,000 | $5.14M | $8.52M | - | $3.37M | 65.56% | -7.49% |
AMZN Amazon.com Inc | 15,000 | $3.29M | $3.7M | - | $410,850 | 12.48% | +0.26% |
ARGT GLOBAL X MSCI ARGENTINA ETF | 12,600 | $1.16M | $1.09M | - | -$66,040.51 | -5.72% | -0.023% |
ARKG ARK Genomic Revolution ETF | 120,000 | $3.48M | $6.39M | - | $2.91M | 83.76% | -0.225% |
ARKX ARK Space & Defense Innovation ETF | 40,000 | $616,500 | $1.28M | - | $667,100 | 108.21% | +0.062% |
ASPI ASP Isotopes Inc. | 100,000 | $663,500 | $279,500 | - | -$384,000 | -57.87% | +7.5% |
AVAV AeroVironment Inc. | 70,000 | $8.46M | $10.21M | - | $1.76M | 20.79% | -0.903% |
AXON Axon Enterprise, Inc. | 10,000 | $4.25M | $4.25M | - | $5,400 | 0.13% | +0.115% |
BCX BlackRock Resources & Commodities Strategy Trust | 204,174 | $1.67M | $2.44M | - | $764,298.81 | 45.73% | -0.417% |
BHP BHP Group Ltd. | 40,000 | $2.11M | $3.4M | - | $1.29M | 61.18% | +0.556% |
BIIB Biogen Inc. | 10,000 | $1.83M | $2.25M | - | $415,600 | 22.67% | -1.653% |
BMY Bristol-Myers Squibb Company | 170,000 | $8.37M | $10.71M | - | $2.34M | 27.98% | -1.362% |
BP BP p.l.c. Sponsored ADR | 200,000 | $6.5M | $8.75M | - | $2.25M | 34.71% | -1.53% |
COP ConocoPhillips | 55,000 | $4.24M | $6.88M | - | $2.65M | 62.49% | -0.706% |
CP Canadian Pacific Kansas City Limited | 40,300 | $3.26M | $3.5M | - | $242,203 | 7.44% | +0.254% |
CPB The Campbell's Company | 95,000 | $2.65M | $1.91M | - | -$742,467.54 | -28.01% | +0.249% |
CRSP Crispr Therapeutics AG | 35,100 | $1.67M | $1.92M | - | $253,831 | 15.2% | +1.331% |
CVS CVS Health Corporation | 10,000 | $448,913.04 | $866,050 | - | $417,136.96 | 92.92% | -1.417% |